Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Super-Resolution Ultrasound Imaging for Assessing Response to Neoadjuvant Chemotherapy in Breast Cancer

28. května 2026 aktualizováno: Wang Xiaojing, Anhui Provincial Cancer Hospital

Value of Super-Resolution Ultrasound Imaging in Assessing Response to Neoadjuvant Chemotherapy for Breast Cancer: A Prospective Observational Study

  1. Study Design Overview Study Type: Single-center, prospective, observational, diagnostic study. Primary Objective: To validate whether Super-Resolution Ultrasound Imaging (SRUS) can accurately predict pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer at an early stage (after the first cycle of chemotherapy).

    Sample Size: A total of 150 patients are planned to be enrolled. Study Period: March 2026 - March 2028.

  2. Core Methodology: Cohort Allocation This study employs a classic "Model Development-Validation" cohort design to construct a predictive model and verify its generalizability.

    Allocation Method: Systematic random allocation. Allocation Ratio: 7:3. Randomization: Patients will be assigned based on the sequence of enrollment using a computer-generated random sequence.

    Blinding Principle: Allocation information will be concealed (blinded) from patients and the clinical treatment team. Only the research coordinators and statisticians will have access to the grouping data to prevent information leakage.

    Validation Set (Independent Validation Cohort): Comprising 30% of the sample (45 cases). The data will remain "sealed" until model construction is finalized. It will be used for unbiased, objective performance evaluation of the final model (e.g., calculating AUC, sensitivity).

  3. Study Procedures and Visits

    The study workflow strictly adheres to the chemotherapy timeline, with core data collection points focused on the early phase of treatment:

    V0 (Screening): Confirmation of eligibility criteria. V1 (Baseline, Pre-chemotherapy): Initial SRUS examination to acquire baseline tumor data.

    V2 (Early Visit, 48-72 hours after the 1st cycle): The critical data point for the predictive model; the first follow-up examination.

    V3 (Mid-term Visit, Pre-4th cycle): The second follow-up examination. V4 (Surgery, 3-4 weeks after the last cycle): Radical surgery is performed. V5 (Endpoint Assessment, 2-4 weeks post-surgery): Acquisition of pathological results to confirm pCR status (the gold standard).

  4. Key Technology and Statistics Key Technology: The Mindray Resona A20 ultrasound system will be used in conjunction with Sulfur Hexafluoride (SF6) microbubble contrast agents to extract quantitative parameters such as tumor microvascular density and blood volume.

    Statistical Analysis:

    In the Training Set: LASSO regression will be used for feature selection to construct a logistic regression predictive model.

    In the Validation Set: The formula derived from the training set will be directly applied to calculate the Area Under the ROC Curve (AUC), calibration curves, and other metrics to evaluate model performance.

  5. Eligibility Criteria Inclusion Criteria: Females aged 18-75, histologically confirmed invasive breast cancer, scheduled for standard neoadjuvant chemotherapy, with lesions clearly visible on baseline ultrasound.

Exclusion Criteria: History of prior breast cancer treatment (surgery, radiotherapy, chemotherapy), presence of other active malignancies, pregnancy or lactation, severe organ dysfunction, or poor image quality.

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Detailní popis

Background and Rationale Breast cancer is the most common malignancy among women worldwide. Neoadjuvant chemotherapy (NAC) is standard for locally advanced breast cancer, aiming to downstage tumors and increase surgical options. Conventional imaging modalities (ultrasound, MRI) have limitations in detecting early microvascular changes and residual disease. Super-resolution ultrasound imaging (SRUS) is an emerging technique based on ultrasound localization microscopy, enabling visualization of microvasculature at micron-scale resolution. It provides quantitative parameters including vessel density, blood volume, vascular complexity, perfusion index, and intensity analysis. Preliminary evidence suggests SRUS can detect early microvascular alterations before morphological changes become apparent, but prospective data in breast cancer NAC response prediction are lacking.

Study Design Single-center, prospective, observational, diagnostic study. Patients receive standard NAC per clinical guidelines; no treatment intervention is imposed. The study involves additional SRUS examinations at predefined time points.

Model Development and Validation

Consecutive eligible patients are enrolled and randomly assigned (7:3 ratio using computer-generated sequence) to:

Training set (70%, n=105): for model development, feature selection, and internal optimization.

Validation set (30%, n=45): for independent, unbiased performance validation.

Allocation is concealed from patients and clinical care team. Analysis of SRUS images and pathological assessment are blinded to clinical data and group assignment.

Technical Procedures

Equipment: Mindray Resona A20 ultrasound system, probe frequency 5-18 MHz.

Contrast agent: 4.8 mL sulfur hexafluoride microbubbles (SonoVue) injected intravenously, followed by 5 mL saline flush.

Acquisition: Dynamic image sequences (6 seconds each) are acquired during early arterial phase (10-30 s) and late arterial phase (20-45 s) with breath-holding.

Post-processing: SRIPlatform software extracts quantitative parameters: vessel density, blood volume, vascular complexity, perfusion index, intensity, and velocity. Changes from baseline (Δ%) are calculated.

Study Timeline

V1 (Baseline, within 1 week before NAC): Baseline SRUS.

V2 (Early response, 48-72 hours after cycle 1): First follow-up SRUS (key predictive time point).

V3 (Mid-treatment, before cycle 4): Second follow-up SRUS.

V4 (Surgery, 3-4 weeks after last NAC): Radical breast surgery.

V5 (Pathology, 2-4 weeks post-surgery): Pathological complete response (pCR) determination (reference standard).

Sample Size Based on an assumed pCR rate of 30%, a two-sided 95% confidence interval width of 0.15 for sensitivity (expected 80%), 10% dropout, and 30% allocation to validation set, total enrollment is 150 patients. The training set provides ~32 pCR events, supporting evaluation of 3-5 candidate predictors (event-per-variable rule: 10:1).

Statistical Analysis

Software: R 4.3.0 (glmnet, rms, pROC, rmda).

Variable screening: Univariate analysis (p<0.10), then LASSO regression with 10-fold cross-validation (λ.1se) for dimension reduction.

Model building: Multivariate logistic regression; coefficients, OR, 95% CI.

Internal validation: Bootstrap optimism-corrected AUC.

External validation: Apply final model to validation set; assess discrimination, calibration, and clinical utility (decision curve analysis).

Reporting: Adherence to TRIPOD statement.

Safety and Risk Mitigation SRUS is non-invasive with output within safe limits, equivalent to conventional ultrasound. Risks are minimal (mild discomfort, potential privacy breach). Data are anonymized and stored on encrypted hospital servers.

Quality Control

Standardized operating procedures for image acquisition and post-processing.

Operator training and inter-operator consistency testing.

Image quality review by core laboratory (signal-to-noise ratio, tracking stability, coverage of inflow-washout phases).

100% source data verification for key variables.

Quarterly internal audits.

Ethics and Dissemination Approved by the Institutional Ethics Committee of the First Affiliated Hospital of USTC (West District, Anhui Provincial Cancer Hospital). Conducted in accordance with the Declaration of Helsinki. Written informed consent obtained from all participants. Results will be submitted for publication in peer-reviewed journals regardless of outcome.

Study Period March 2026 - March 2028.

Typ studie

Pozorovací

Zápis (Odhadovaný)

150

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

  • Čína
    • Anhui
      • Hefei, Anhui, Čína, 230001
        • Anhui Provincial Cancer Hospital
        • Kontakt:

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dospělý
  • Starší dospělý

Přijímá zdravé dobrovolníky

Ne

Metoda odběru vzorků

Vzorek nepravděpodobnosti

Studijní populace

This study will enroll female patients aged 18 to 75 years with histologically confirmed invasive breast cancer who are scheduled to receive neoadjuvant chemotherapy (NAC) prior to surgery.

Participants must have at least one measurable tumor lesion suitable for super-resolution ultrasound imaging. Patients with evidence of distant metastasis (Stage IV) or those who have received prior systemic therapy for the current cancer diagnosis will be excluded.

The study aims to recruit approximately 150 participants from the Anhui Provincial Cancer Hospital. This population represents a typical cohort of locally advanced breast cancer patients undergoing standard NAC protocols.

Popis

Inclusion Criteria

  1. Age and Gender: Female patients aged 18 to 75 years.
  2. Diagnosis: Histologically confirmed invasive breast cancer via core needle biopsy.
  3. Treatment Plan: Scheduled to receive standard neoadjuvant chemotherapy at our institution.
  4. Imaging: The lesion is clearly visible on baseline ultrasound. Consent: Willing to participate in the study and sign the written informed consent form.

Exclusion Criteria

  1. Prior Treatment: History of any prior treatment for ipsilateral breast cancer (e.g., surgery, radiotherapy, chemotherapy, or targeted therapy).
  2. Other Malignancies: Presence of other active malignancies.
  3. Pregnancy/Lactation: Pregnant or breastfeeding women.
  4. Health Status: Severe cardiac, hepatic, or renal insufficiency, or psychiatric disorders that preclude cooperation with the examination.
  5. Image Quality: Poor ultrasound image quality that prevents SR-US analysis.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

Kohorty a intervence

Skupina / kohorta
Training set (development queue)
70% of the total sample size (planned to include 105 cases) will be used for constructing predictive models, feature screening (such as using LASSO regression), and internal optimization.
Verification set (independent verification queue)
Training Set (Development Cohort): Participants assigned to this group constitute 70% of the total sample (n=105). Data from this group are used for model development, feature selection, and internal optimization. Allocation is performed by a computer-generated random sequence (7:3 ratio) at enrollment. The group assignment is concealed from patients and the clinical care team. Validation Set (Independent Validation Cohort): Participants assigned to this group constitute 30% of the total sample (n=45). Data from this group are reserved for unbiased, independent performance validation of the final prediction model. Allocation is performed by a computer-generated random sequence (7:3 ratio) at enrollment. The group assignment is concealed from patients and the clinical care team.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Discriminative Ability of the Super-Resolution Ultrasound Prediction Model for Pathological Complete Response (pCR)
Časové okno: Through study completion, an average of 24 weeks
The discriminative ability of the final prediction model (derived from super-resolution ultrasound parameters) in identifying pCR, assessed in the independent validation cohort. Performance is quantified by the Area Under the Receiver Operating Characteristic Curve (AUC). An AUC value closer to 1 indicates stronger discriminative ability.
Through study completion, an average of 24 weeks

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Diagnostic performance of the model.
Časové okno: Through study completion, an average of 24 weeks
In the validation set, the optimal cutoff value is determined using the Youden index. Performance metrics including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) are calculated.
Through study completion, an average of 24 weeks
Predictive value of early parameter changes.
Časové okno: 3 weeks
The ability of early changes in super-resolution ultrasound parameters (measured after the first chemotherapy cycle) to predict final pCR status. Evaluated using univariate ROC analysis to calculate the AUC.
3 weeks
Diagnostic Accuracy, Sensitivity, and Specificity of SRUS Model for pCR
Časové okno: Through study completion, an average of 24 weeks
The secondary outcomes include the diagnostic accuracy, sensitivity, and specificity of the SRUS prediction model. These metrics will be calculated based on the confusion matrix derived from the independent validation cohort.
Through study completion, an average of 24 weeks
Clinical utility of the model.
Časové okno: Through study completion, an average of 24 months
The net clinical benefit of using the prediction model to guide clinical decision-making, assessed across a range of threshold probabilities. Evaluated using Decision Curve Analysis (DCA).
Through study completion, an average of 24 months

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Anhui Provincial Cancer Hospital

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. června 2026

Primární dokončení (Odhadovaný)

1. března 2028

Dokončení studie (Odhadovaný)

1. července 2028

Termíny zápisu do studia

První předloženo

7. května 2026

První předloženo, které splnilo kritéria kontroly kvality

28. května 2026

První zveřejněno (Aktuální)

3. června 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

3. června 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

28. května 2026

Naposledy ověřeno

1. května 2026

Více informací

Termíny související s touto studií

Klíčová slova

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • 2026-LLYJ-0025

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na Rakovina prsu

Prohledejte podobné pokusy

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

CROs by country

CROs in Nigeria

Podmínky

Vzácné nemoci

Drogové intervence

Doplňky stravy

Sponzor / Spolupracovníci

Místa

Předplatit